| HA |
HBV, HCV, AC, NAFLD |
Liver fibrosis stage evaluation by increased HA concentration |
(12, 13, 20, 21, 27, 32, 33) |
| HA |
HBV, HCV, NAFLD |
Healthy patients screening; differentiation from patients with liver fibrosis |
(14, 16, 24, 28, 30) |
| HA |
HBV |
Monitoring of antiviral treatment |
(17, 18) |
| LN |
HCV, HBV |
Liver fibrosis stage evaluation by increased LN concentration |
(12, 40-43) |
| LN |
HBV |
Monitoring of antiviral treatment |
(46) |
| PIIIP N-P |
HBV, AC |
Healthy patients screening; differentiation from patients with liver fibrosis |
(49-51) |
| PIIIP N-P |
|
Screening for MTX induced hepatic fibrosis |
(53, 54) |
| CIV |
HCV, HBV |
Liver fibrosis stage evaluation by increased CIV concentration |
(41, 59) |
| CIV |
HBV, NASH |
Healthy patients screening; differentiation from patients with liver fibrosis |
(50) |
| CG |
NA |
Healthy patients screening; differentiation from patients with liver fibrosis |
(62) |
| HA - hyaluronic acid. LN - laminin. PIIIP N-P - collagen type III N-peptide. CIV - type IV Collagen. CG - cholylglycine. HBV - hepatitis B virus, HCV - hepatitis C virus. AC - alcoholic cirrhosis. NAFLD - non-alcoholic fatty liver disease. MTX - methotrexate. NASH - non-alcoholic steatohepatitis. NA – not available. |
